Sarcomatrix Therapeutics Opens Accredited Investor Round for Once-Daily Pill to Address Duchenne Across Genetic Mutation

Sarcomatrix opens its accredited investor round to advance S-969, a once-daily, mutation-agnostic oral therapy for Duchenne toward human trials.

RENO, NV, UNITED STATES, July 24, 2026 /EINPresswire.com/ -- FOR IMMEDIATE RELEASE

Sarcomatrix Therapeutics Opens Accredited Investor Round for Once-Daily Duchenne Candidate Designed to Work Regardless of Mutation

With over 7,000 known mutations in the Duchenne gene alone, most therapies reach only a fraction of patients. Sarcomatrix's first-in-class candidate takes a different approach. The round closes September 30, 2026.

RENO, Nev., July 24, 2026 -- Sarcomatrix Therapeutics Corp., a Delaware corporation, today announced its Regulation D, Rule 506(c) round is open to verified accredited investors at sarcomatrix.com/investors, on the KoreConX platform with KoreTransfer USA LLC as transfer agent. Sarcomatrix is preclinical-stage: its treatments have not been tested in people. It expects to ask the FDA for permission to begin human testing in early 2027.

WHY MOST DRUGS REACH FEW PATIENTS

Duchenne muscular dystrophy, which mostly affects boys, leaves muscle fibers without a protective protein, so ordinary movement causes damage faster than the body repairs it. Most patients lose the ability to walk in their teens. There is no cure.

The obstacle is genetic variety. Duchenne stems from thousands of errors in one gene, over 7,000 identified so far, and muscular dystrophy spans more than 30 conditions with over 10,000 catalogued mutations.* Most therapies correct

one specific error, so each reaches a fraction of patients. The rest wait for a drug that may never come.

A DIFFERENT APPROACH

S-969, Sarcomatrix's lead candidate, is a novel, first-in-class once-daily oral pill. Rather than fixing the broken gene, it targets alpha-7 beta-1 integrin, a protein that both anchors muscle fibers to surrounding tissue and signals the muscle's own repair process. Because it does not depend on a patient's mutation, it is designed to be relevant across the population, and is in development for Duchenne, Becker, and limb-girdle muscular dystrophy 2I/R9.

WHERE THINGS STAND

Laboratory and animal research is complete. The company plans to file with the FDA in Q1 2027, begin first-in-human dosing in Q2 2027 at Nucleus Network in Melbourne, Australia, and reach an initial patient readout by late 2028. These are plans, not guarantees.

-- Investors include Prevail Partners as co-lead, Battle Born Venture, and Research Affiliates Capital, with roughly $8.9 million invested to date including non-dilutive NIH funding.

-- LAM-111, a second program, holds Orphan Drug Designation in both the United States and the European Union; an application is in progress for S-969.

-- A University of Nevada, Reno spinout, holding its programs under a worldwide exclusive license through the Nevada Research and Innovation Corporation, with 75-plus patents filed.

MARKET OUTLOOK

Independent analyses estimate the global Duchenne treatment market at roughly $3 billion to $5 billion today and $8 billion to $12 billion by 2030, with growth continuing to 2035.** The company estimates an initial commercial population of about 30,000 patients in the United States, Canada, and Western Europe, within roughly 48,000 addressable across North America and Europe.***

These figures describe the market, not Sarcomatrix revenue. The company has no approved products, may never obtain approval, and may never capture any share of this market.

"Families living with Duchenne are running a clock that does not stop while the science catches up," said David Craig, Co-Founder, President and Chief Executive Officer. "This round funds the step where laboratory work becomes a real trial in real patients."

UNDERSTAND THE RISKS

Sarcomatrix has no approved products or revenue, and its treatments have never been tested in humans. Most experimental drugs fail. You could lose your entire investment, a realistic outcome in early-stage biotechnology. There is no public market for these shares and none is expected. Timelines commonly slip. Only invest what you can afford to lose entirely.

HOW TO PARTICIPATE

The offering is open only to accredited investors as defined by the SEC. Under Rule 506(c), self-certification is not sufficient; verification runs through the offering platform, and full terms and risk disclosures follow on KoreConX once verified. Begin at sarcomatrix.com/investors. The round closes September 30, 2026, subject to earlier closing if fully subscribed or extension at the Company's discretion.

ABOUT SARCOMATRIX

Sarcomatrix Therapeutics Corp., a Delaware corporation headquartered in Reno, Nevada, is a preclinical-stage company developing novel, first-in-class treatments for rare muscle-wasting diseases including Duchenne, Becker, LGMD2I/R9, and LAMA2-related CMD. sarcomatrix.com

INVESTOR RELATIONS

Ray Jordan
President, Investor Relations, Putnam Insights
ir@sarcomatrix.com

* Type counts per Cleveland Clinic and NYU Langone; variant counts per TREAT-NMD and the Leiden Open Variation Database. The 10,000 figure spans the muscular dystrophies collectively, not the Duchenne gene alone. ** Range of published third-party estimates (Grand View, Mordor, Market Research Future, DataM). *** Company estimates.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements regarding product candidates, regulatory plans, timelines, market and population estimates, and potential additional indications. These involve significant risks and uncertainties inherent in drug development, regulatory review, and financing, and actual results may differ materially. Product candidates are investigational and have not been approved by any regulatory authority. Laboratory and animal results are not necessarily predictive of results in humans. Market and population estimates derive from third-party sources and company assumptions, and are not projections of company revenue. Forward-looking statements speak only as of the date made, and the company undertakes no obligation to update them except as required by law.

OFFERING DISCLAIMER

This communication is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities. Any offer or sale is made solely pursuant to Rule 506(c) of Regulation D under the Securities Act of 1933, as amended, and only to persons whose accredited investor status has been verified. The securities are not registered under the Securities Act or any state securities laws and are offered in reliance on exemptions from registration. No securities regulator has approved this offering or passed upon the accuracy of any offering materials. Investment in an early-stage, preclinical biotechnology company involves a high degree of risk, including possible loss of the entire investment, and there is no public market for these securities. Prospective investors should review the offering materials and consult their own legal, tax, and financial advisors.

###

David Craig
Sarcomatrix, Inc.
+17755251795 ext.
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
X

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.